Ftse Mib
33.746,66
0,00%
DAX
17.921,95
0,00%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.592,22
-1,11%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AcelRX Pharmaceuticals Inc (ACRX) AcelRX Pharmaceuticals Inc (ACRX) Notizie

AcelRX Pharmaceuticals Inc

ACRX
0,86
0,00 (0,00%)
01 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202422:25EDGAR2Form ARS - Annual Report to Security Holders
29/4/202422:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/4/202422:23EDGAR2Form DEF 14A - Other definitive proxy statements
19/4/202422:37EDGAR2Form 8-K - Current report
21/3/202421:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/3/202421:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:17EDGAR2Form 8-K - Current report
09/1/202415:05PRNUSAcelRx Announces Rebranding With Name Change to Talphera,..
14/12/202314:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202314:30PRNUSAcelRx Pharmaceuticals Announces Publication of Study..
22/11/202322:38EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202322:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:14EDGAR2Form 8-K - Current report
08/11/202322:05PRNUSAcelRx Reports Third Quarter 2023 Financial Results and..
07/11/202322:05PRNUSAcelRx to Host KOL Panel Discussion on Current Anticoagulant..
26/10/202322:30PRNUSAcelRx to Host Third Quarter 2023 Financial Results Call and..
20/10/202322:30EDGAR2Form 8-K - Current report
10/10/202322:17EDGAR2Form 8-K - Current report
05/10/202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202322:30EDGAR2Form 8-K - Current report
03/10/202314:30PRNUSAcelRx Receives IDE Approval for Niyad and Advances to a..
22/9/202323:18EDGAR2Form 8-K - Current report
12/9/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202314:30PRNUSAcelRx Pharmaceuticals to Participate in the H.C. Wainwright..
28/8/202312:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202312:34EDGAR2Form DEF 14A - Other definitive proxy statements
25/8/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202318:45EDGAR2Form 144 - Report of proposed sale of securities
24/8/202322:23EDGAR2Form 144 - Report of proposed sale of securities
10/8/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:10EDGAR2Form 8-K - Current report
10/8/202322:05PRNUSAcelRx Reports Second Quarter 2023 Financial Results and..
09/8/202323:29EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
02/8/202312:06EDGAR2Form S-3 - Registration statement under Securities Act of..
27/7/202322:05PRNUSAcelRx to Host Second Quarter 2023 Financial Results Call..
21/7/202314:15EDGAR2Form 8-K - Current report
21/7/202314:00PRNUSAcelRx Pharmaceuticals Announces Closing of Previously..
18/7/202314:00PRNUSAcelRx Pharmaceuticals Announces $10 Million Private..
10/5/202322:05PRNUSAcelRx Pharmaceuticals Reports First Quarter 2023 Financial..
Apertura: Min: Max:
Chiusura: 0,86

La tua Cronologia

NASDAQ
ACRX
AcelRX Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network